Nesher Technologies, Inc.
Nanobiotech for smarter diagnostics and cutting-edge biomedical research

  • Advancing Technology to Save Lives

    Research and development activities on instrumentation and reagent development for medical diagnostics in the areas of oncology, diabetes, infectious and autoimmune diseases, neurogenetic disorders, and bioterror threats, as well as on instrumentation for life sciences applications.

  • In Vitro Diagnostics (IVD)

    NTI’s long-term goal is to develop simple, rapid, highly multiplexed (with a capacity of ≥100 analytes per sample), ultrasensitive and -specific, quantitative, cost-effective, and fully automated, nucleic acid- and protein-based syndrome-driven in vitro diagnostic tests.

  • Research and Drug Discovery

    The ALEX technology’s unique single molecule analysis power allows to monitor molecular dynamics on the nanometer scale. The ALEX technology is highly useful in basic research for characterization of complex biological processes such as replication, recombination, transcription, translation, protein maturation, signal transduction, and others, in normal and disease states.

  • ALEX Spectroscopy

    NTI offers in-house services for ALEX measurements of submitted samples. The NTI Service Laboratory provides a full range of sample testing services for your research project.
  • 1
  • 2
  • 3
  • 4
Nesher Technologies, Inc. (NTI) is an exciting, cutting-edge early-stage nanobiotech company which employs a proprietary single molecule detection (SMD) technology for development of next-generation diagnostic and analytical systems. It is the first true SMD technology platform that can detect both protein- as well as nucleic acid-based targets in a multiplexed fashion1.

Home

Our Mission
NTI's mission is to become a global leader in SMD and revolutionize healthcare by empowering clinicians and researchers with the most sensitive, specific, and cost-effective diagnostic and analytical tools to detect disease at its earliest and most treatable stage. NTI’s goal is to commercialize automated, highly multiplexed protein- and nucleic acid-based diagnostic tests which can simultaneously detect and accurately quantify multiple biomarkers, pathogens, and/or genetic aberrations in very small patient samples.

The Technology
NTI obtained an exclusive license for the patented Alternating Laser EXcitation (ALEX) technology, a SMD method based on multi-color fluorescence spectroscopy with vast commercial potential. NTI employs this new platform technology for development of analytical and diagnostic systems for various applications, consisting of spectroscopic analyzer instruments and reagent kits, and offers various services. The ALEX technology is a unique SMD technology for ultrasensitive, specific, and highly multiplexed barcoded detection and quantification of target molecules such as proteins, RNAs (including microRNAs), and DNAs in complex samples. Diagnostic application examples include tests for early cancer detection, acute myocardial infarction, osteoarthritis, traumatic brain injury, neurodegenerative diseases such as Alzheimers, Parkinsons, and other motosensory neuropathies, diabetes, asthma, infectious and autoimmune diseases, as well as bioterror agents.

The technology also provides information about molecular interactions and dynamics to investigate biological mechanisms and analyze conformations of biomolecules using single molecule fluorescence resonance energy transfer (smFRET). The high-resolution power for monitoring molecular dynamics and interactions allows viewing of biomolecular machineries in action, a unique breakthrough highly useful in multiple life sciences applications. It will also greatly aid structure-activity relationship (SAR) studies for drug discovery/lead optimization applications, opening new avenues for structure-guided rational drug design. In academia, ALEX has been used already extensively to study molecular dynamics of important complex biological processes such as gene transcription and biomolecular folding2-4.

The ALEX single molecule fluorescence spectroscopy instrumentation (“Analyzer”), advanced to four-colors (4c-ALEX) by NTI, is currently available as a research-grade prototype. NTI has secured several small business grants from the National Institutes of Health, published its proof-of-principle studies, and is expanding its IP position.

1. S. W. Yim et al., Clin Chem 58, 707 (2012)
2. A. N. Kapanidis et al., Science 314, 1144 (2006)
3. A. Chakraborty et al., Science, 337, 591 (2012)
4. X. Michalet et al.,Chemical reviews 106, 1785 (2006)

FacebookTwitterDiggStumbleuponTechnoratiLinkedin

Enabling Personalized Medicine

original image

In the News

  • 29 July 2015 +

    NTI receives SBIR grant funding from the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to develop an innovative test for early diagnosis of Systemic Lupus Erythematosus (SLE), an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue, implementing a panel of microRNA and autoantibody biomarkers and overcoming limitations of current SLE testing.

  • 26 August 2013 +

    NTI receives SBIR grant funding from the NIH/National Institute on Aging (NIA) to develop a multiplexed protein and microRNA biomarker-based next-generation test for Alzheimers Disease (AD), expected to improve early disease detection and implementation of optimized patient management strategies.

  • 16 September 2013 +

    NTI receives SBIR grant funding from the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to develop a multiplex protein and microRNA biomarker-based test for protease activity profiling in arthritic joints which should prove highly useful for drug development and personalized treatments.

  • 15 September 2015 +

    NTI receives Small Business Innovative Research (SBIR) grant funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) to develop a multiplexed autoantibody and microRNA biomarker-based next-generation test for Type 1 Diabetes (T1D), previously known as juvenile diabetes, in order to better assist in establishing early diagnosis of T1D, refine prognosis, guide management, target treatment, and improve patient outcome.

  • 03 August 2012 +

    A team of researchers, including NTI's Principal Scientist Dr. Taiho Kim, publishes its break-through discovery in the prestigious journal Science, obtained using an advanced ALEX spectroscopy intrumentiation established by NTI. (Chakraborty, A., Wang, D., Ebright, Y.W., Korlann, Y., Kortkhonjia, E., Kim, T., Chowdhury, S., Wigneshweraraj, S., Irschik, H., Jansen, R., Nixon, B.T., Knight, J., Weiss, S. & Ebright, R.H. Opening and Closing of the Bacterial RNA Polymerase clamp. Science, 337, 591-595 (2012))
  • 1
  • 2
› ‹